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Abstract
Malan syndrome is an overgrowth disorder described in a limited number of individuals. We aim
to delineate the entity by studying a large group of affected individuals. We gathered data on 45
affected individuals with a molecularly confirmed diagnosis through an international collabora-
tion and compared data to the 35 previously reported individuals. Results indicate that height
is > 2 SDS in infancy and childhood but in only half of affected adults. Cardinal facial characteris-
tics include long, triangular face,macrocephaly, prominent forehead, everted lower lip, and promi-
nent chin. Intellectual disability is universally present, behaviorally anxiety is characteristic.Malan
syndrome is caused by deletions or pointmutations ofNFIX clusteredmostly in exon 2. There is no
genotype-phenotype correlationexcept for an increased risk for epilepsywith19p13.2microdele-
tions. Variants arose de novo, except in one family in which mother was mosaic. Variants causing
Malan andMarshall-Smith syndrome can be discerned by differences in the site of stop codon for-
mation.We conclude thatMalan syndrome has a well recognizable phenotype that usually can be
discerned easily fromMarshall–Smith syndrome but rarely there is some overlap. Differentiation
from Sotos andWeaver syndrome can bemade by clinical evaluation only.
K EYWORDS
Malan syndrome, Marshall-Smith syndrome, NFIX, phenotype, phenotype-genotype, Sotos
syndrome,Weaver syndrome
1 INTRODUCTION
Overgrowth has been defined as “global or regional excess growth
compared either to an equivalent body part or the age-related peer
group” (Tatton-Brown & Weksberg, 2013). Overgrowth syndromes
form a group of genetically determined disorders in which at least
height is equal to or greater than two standard deviations (SDS)
above the mean, but also weight and head circumference may be
increased, and the growth pattern is typically present from birth on.
The overgrowth may or may not be associated with malformations or
dysplasias.
Malan syndrome (MIM# 614753; also called as Sotos syndrome 2)
is an overgrowth disorder, characterized by overgrowth, an unusual
facial phenotype, intellectual disability, and behavioral problems. It is
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caused by heterozygous variants or deletions of the gene nuclear fac-
tor I X (NFIX; MIM# 164005), located at chromosome 19p13.2 (Malan
et al., 2010). Since the first description the entity has been described in
35 individuals, to date (Auvin, Holder-Espinasse, Lamblin, & Andrieux,
2009; Bonaglia et al., 2010; Dolan et al., 2010; Dong et al., 2016; Gurri-
eri et al., 2015; Jezela-Stanek et al., 2016; Jorge et al., 2015; Klaassens
et al., 2015; Kuroda et al., 2017; Lu et al., 2017; Lysy et al., 2009;
Martinez et al., 2015; Natiq et al., 2014; Nimmakayalu et al., 2013;
Oshima et al., 2017; Priolo et al., 2012; Shimojima et al., 2015; Yoneda
et al., 2012). Haploinsufficiency of NFIX has been proposed as lead-
ing causative mechanism in Malan syndrome (Gurrieri et al., 2015;
Klaassens et al., 2015; Malan et al., 2010). The syndrome is allelic
to Marshall-Smith syndrome (MIM# 602535) (Martinez et al., 2015;
Schanze et al., 2014; Shaw et al., 2010), characterized by a dysosto-
sis, postnatal failure to thrive, short stature, unusual face, respiratory
compromise, andmoderate to severe developmental delay (Shawet al.,
2010; Van Balkom et al., 2011). NFIX variants in Marshall-Smith syn-
drome were predicted to lead to abnormal proteins with an abnor-
mal C-terminus while their DNA binding and dimerization domain was
preserved. Some variants escape nonsense-mediated mRNA decay
(NMD), suggesting a dominant-negative effect of mutant NFIX pro-
teins (Malan et al., 2010; Schanze et al., 2014).
Here, we report on 45 individuals with Malan syndrome (14 being
mentioned in a table without clinical data (Tatton-Brown et al., 2017),
the others unpublished), provide detailed clinical descriptions and
their genotypes, review earlier reported patients, and compare data
to those of Marshall–Smith syndrome and to Sotos syndrome and
Weaver syndrome (MIM# 277590). We refine genotype-phenotype
correlations in individuals with disease-causingNFIX variants.
2 METHODS
2.1 Patients
Patients were referred for clinical (R.C.H., M.P) or molecular (M.P.,
M.Z.) diagnosis, management advices (R.C.H.), or specifically for this
study. Patients were typically recognized by their referring physi-
cians using targeted exome sequencing aimed at detecting causes
for intellectual disability. In three patients, a clinical diagnosis of
Malan syndrome was molecularly confirmed by targeted Sanger
sequencing.
A dedicated questionnaire was used to gather clinical and molecu-
lar data, and clinical photographs were available on every patient. The
facial characteristics were scored independently by two authors (M.P.,
R.C.H.). In case of inconsistencies in scoring these were discussed till
consensus.
2.2 Molecular studies
Sanger sequencing and exome sequencing were performed according
to local protocols. Confirmation of exome results by Sanger sequenc-
ingwasperformed inmost patients, unless exome resultswere thought
sufficiently reliable. Microdeletions were identified by array CGH or
SNP array.
Total RNA was extracted from skin fibroblast cultures and cDNA
was generated using the SuperScriptTM First-Strand Synthesis Sys-
tem (Thermo Fisher). Specific oligonucleotide primer combinations
were used to amplify cDNA fragments of interest, allowing discrimina-
tion between different NFIX transcript isoforms (Supporting Informa-
tion Figure 1). Analysis of these fragments was performed by Sanger
sequencing.
2.3 In silico analysis of mutant NFIX proteins
Combined Annotation Dependent Depletion (CADD; version 1.3;
https://cadd.gs.washington.edu/) scores were used as tool for scor-
ing deleteriousness of all variants (Kircher et al., 2014). We per-
formed in silico analysis of predicted mutant cDNAs after ExPASy
translation and alignment with wild-type protein by Clustal Omega
(v1.2.4; https://www.ebi.ac.uk/Tools/msa/clustalo/) for short inser-
tions/deletions located in exons 6, 7, and 8 and in variants associated
with Marshall-Smith syndrome. We performed in silico alignment by
ClustalOmegaof humanNFIXprotein isoformsencodedby transcripts
reported in Ensembl Genome Browser 90 and alignment of paraloges
and orthologes to humanNFIX.
2.4 Literature search
PubMed was searched for publications using as terms “Malan syn-
drome” OR “Malan overgrowth” OR “Sotos type 2″ OR “Sotos type
II” OR “NFIX overgrowth” OR “deletion 19p13.2″ OR “microdeletion
19p13.2″. Exclusion criterion was publication in a language other than
English, French, Dutch, Italian, Spanish, or Portuguese. Reference lists
of thus obtained manuscripts were hand searched for further refer-
ences.Weexcluded reports describing deletions extending centromer-
ically > 1 Mb from NFIX because of the large number of potentially
confounding genes. Facial phenotypes of patients depicted in publica-
tions were scored independently by two authors (M.P., R.C.H.). Avail-
able descriptions of phenotypes were accepted unless photographic
evidence of differences was clear.
2.5 Ethics
All participants or their legal guardians gave written informed consent
for molecular analyses and publication of clinical and genotype data
and facial photographs. The study was approved by the medical ethics
committee of Great Metropolitan Hospital Bianchi-Melacrino-Morelli
in Reggio Calabria (N◦200 approval).
3 RESULTS
We collected 45 patients with molecularly confirmed Malan syn-
drome. Three had variably sized microdeletions involving 19p13.2
and 42 had variants in NFIX. Literature searches yielded 21 patients
with microdeletions involving 19p13.2 and 14 patients with intragenic
NFIX variants. A summary of main clinical characteristics compared to
those inMarshall-Smith syndrome (Shaw et al., 2010), Sotos syndrome
(Tatton-Brown et al., 2007) and Weaver syndrome (Tatton-Brown
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TABLE 1 Comparison of characteristics of Malan syndrome caused by NFIX mutations and by deletions of the complete gene, to those of
Marshall-Smith syndrome, Sotos syndrome, andWeaver syndrome
Malan syndrome
NFIX
mutations
NFIX
deletions All
Marshall-
Smith
syndrome
Sotos
syndrome
Weaver
syndrome
Growth Prenatal:Weight at
birth< 2SDS
0 0 0 11/55 - -
Prenatal:Weight at
birth> 2SDS
5/54 6/21 11/75 8/55 +++a ++
Postnatal:
Height< 2SDS
0 0 0 38/39 - -
Postnatal:
Height> 2SDS
31/55 13/24 44/79 0/18 +++ +++
Development Intellectual
disability/global
developmental delay
56/56 24/24 80/80 39/39 +++b +++c
Autistic features (A)/
anxieties (F)
A 18/52; F
34/54
A 5/22;F 6/21 A 23/74; F
40/75
Na ? (F)+
Neurology Hypotonia (Ho)/
hypertonia (He)
Ho 36/51; He
n.a
Ho 21/24; He
n.a
Ho 57/75 Ho12/28
He4/28
Ho++ Ho++, He++
Seizures/EEG
anomalies
10/55 11/24 21/79 4/38 ++ -
Brain anomalies:
WV/C/BA/CM
19/44 13WV;
8C; 3CM
11/19 4WV;
6C; 2BA; 3CM
30/63 17WV;
14C; 2BA;
6CM
12/39 C 8; SC
1;WV
WV++, C-;
BA-; CM-
+
Craniofacial
morphology
Macrocephaly 44/55 16/24 60/79 0/39 +++ ++
Long/triangular face 47/55 20/24 67/79 0/57 +++ -
Prominent forehead 53/55 24/24 77/79 53/54 +++ +++
Proptosis 0 1/23 1/78 55/56 - -
Underdeveloped
midface
0 0 0 38/42 - -
Short nose 26/54 14/21 40/75 43/50 - +++
Anteverted nares 28/54 15/22 43/76 44/53 - +++
Everted lips 40/54 14/21 54/75 13/19 + -
Small chin; prominent
chin
1/55; 41/55 1/24; 16/21 2/79; 57/76 55/57 - +++
Eyes Vision impaired 42/56 18/24 60/80 9/18 + +
Blue sclerae 15/52 4/14 19/66 34/41 - -
Respiratory tract Airway obstructions 1/55 0 1/78 45/55 - -
Musculo-skeletal
anomalies
Abnormal bone
maturation
29/38 11/12 40/50 57/57 +++ +++
Slender habitus 35/55 11/23 46/78 0/57 ++ -
Kyphoscoliois 18/56 5/16 23/72 17/37 + +
Pectus excava-
tum/carinatum
19/56 11/19 30/75 3/37 + +
Other Hypertrichosis 0 0 0 29/35 - -
Gum hypertrophy 1/55 1/24 2/79 7/17 - -
Cadiac defects 3/55 1/24 4/79 6/35 + -
Umbilical hernia n.a n.a n.a 10/32 + ++
aWeight to length normal as typically length> P98.
bTypically mild (IQ 50–69) or borderline (IQ 70–75).
cTypically mild (IQ 50–69) or moderate (IQ 35–50).
dNo unbiased series of molecularly confirmed patients available;+++75–100%;++ 25–75%;+ 5–25%; - 0–5%.
WV, wide ventricles; C, Corpus callosum underdevelopment; BA, brain atrophy; CM, chiari malformation.
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TABLE 2 Spectrum ofNFIXmutations in 42 presently reported patients and those reported in literature
Patient/ReferencecDNA Protein Location Type ofmutation Inheritance
CADD
PHRED
scoreb
P1 c.[28-1G>A;28-12T>A;28-
13T>A]
p.Asp10Profs*5 Intron 1 Splicing De novo 25
P2 c.43_49dup p.(Glu17Valfs*31) Exon 2 Frameshift De novo 31
P3 c.59T>C p.(Leu20Pro) Exon 2 Missense ND 26
Klaassens 2015 c.90_99del p.(Trp30Cysfs*24) Exon 2 Frameshift De novo 32
P4 c.92T>C p.(Phe31Ser) Exon 2 Missense De novo 26
Martinez 2015 c.112C> T
1published as c.136C> T
p.(Arg38Cys)
1published as p.Arg46Cys
Exon 2 Missense De novo 34
P5 c.112C> T p.(Arg38Cys) Exon 2 Missense DeNovo 34
P6 c.113G> T p.(Arg38Leu) Exon 2 Missense ND 32
P7 c.142del p.(Met48Cysfs*9) Exon 2 Frameshift De novo 28
P8 c.154_155insT p.(Glu52Valfs*67) Exon 2 Frameshift De novo 33
Priolo 2012 c.157_177del p.(Glu53_Glu59del) Exon 2 In frame deletion De novo 16
P9 c.157_177del p.(Glu53_Glu59del) Exon 2 In frame deletion De novo 16
Martinez 2015 c.161G> C
1published as c.185G> C
p.(Arg54Pro)
1published as p.Arg62Pro
Exon 2 Missense De novo 31
Yoneda 2012 c.179T> C p.(Leu60Pro) Exon 2 Missense De novo 26
P10 c.182T>C p.(Leu61Pro) Exon 2 Missense De novo 26
P11 c.187G> T p.(Glu63*) Exon 2 Nonsense De novo 39
Gurrieri 2015 c.191del p.(Lys64Serfs*30) Exon 2 Frameshift De novo 27
P12 c.200_201dup p.(Lys68Serfs*27) Exon 2 Frameshift De novo 31
P13 c.248T>G p.(Ile83Ser) Exon 2 Missense De novo 28
Oshima 2017 c.269dup
1published as c.290_291insA
p.(Asp90Glufs*29)
1published as p.Asp98GlyfsX29
Exon 2 Frameshift De novo 31
P14 c.280A>C p.(Thr94Pro) Exon 2 Missense ND 25
P15 c.294del p.(Phe99Serfs*36) Exon 2 Frameshift De novo 28
P16 c.315_316insGGT p.(Leu105_Ser106insGly) Exon 2 In frame insertion De novo 16
P17 c.317C> T p.(Ser106Phe) Exon 2 Missense ND 28
P18 c.322_323delinsA p.(Pro108Thrfs*27) Exon 2 Frameshift De novo 33
P19 c.325G> T p.(Asp109Tyr) Exon 2 Missense De novo 29
P20 c.328C> T p.(Gln110*) Exon 2 Nonsense De novo 37
P21 c.337A>G p.(Lys113Glu) Exon2 Missense De novo 26
P22 c.343C> T p.(Arg115Trp) Exon 2 Missense De novo 34
Jezela-Stanek
2016
c.343C> Ta
published as c.367C> T
p.(Arg115Trp)a
published as p.Arg123Trp
Exon 2 Missense De novo 34
P23 c.346C>G p.(Arg116Gly) Exon 2 Missense De novo 27
P24 c.347G>A p.(Arg116Gln) Exon 2 Missense ND 30
P25 c.347G>A p.(Arg116Gln) Exon 2 Missense De novo 30
Gurrieri 2015 c.347G> C p.(Arg116Pro) Exon 2 Missense De novo 29
P26 c.358delC p.(Leu120Cysfs*15) Exon 2 Frameshift De novo 33
Yoneda 2012 c.362G> C p.(Arg121Pro) Exon 2 Missense Maternal 30
Gurrieri 2015 c.373A>G p.(Lys125Glu) Exon 2 Missense De novo 26
Lu 2017 c.373G> T p.(Lys125Gln) Exon 2 Missense De novo 26
P27 c.383G>A p.(Arg128Gln) Exon 2 Missense ND 32
P28 c.408delinsTT p.(Lys136Phefs*3) Exon 2 Frameshift ND 31
P29 c.412_413delinsG p.(Lys138Glyfs*73) Exon 2 Frameshift De novo 28
P30 c.444G>C p.(Glu148Asp) Exon 2 Missense De novo 25
P31 c.463C> T p.(Gln155*) Exon 2 Nonsense De novo 37
(Continues)
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TABLE 2 (Continued)
Patient/ReferencecDNA Protein Location Type ofmutation Inheritance
CADD
PHRED
scoreb
P32 c.499C>A p.(His167Asn) Exon 2 Missense De novo 27
P33 c.520G> T p.(Glu174*) Exon 2 Nonsense De novo 38
P34 c.542dup p.(Tyr181*) Exon 2 Frameshift De novo 34
Malan 2010 c.568C> T p.(Gln190*) Exon 3 Nonsense De novo 40
P35 c.694C> T p.(Gln232*) Exon 4 Nonsense Maternal
mosaic
40
P36 c.694C> T p.(Gln232*) Exon 4 Nonsense De novo 40
P37 c.759C>G p.(Tyr253*) Exon 5 Nonsense De novo 37
P38 c.779C>G p.(Thr260Ser) Exon 5 Missense De novo 13
P39 c.859dup p.(Glu287Glyfs*5) Exon 6 Frameshift De novo 35
Klaassens 2015 c.1012C> T p.(Gln338*) Exon 7 Nonsense De novo 42
P40 c.1055_1064del p.(Pro352Leufs*46) Exon 7 Frameshift De novo 36
P41 c.1116del p.(Ser373Profs*28) Exon 8 Frameshift De novo 34
P42 c.1117del p.(Ser373Profs*28) Exon 8 Frameshift De novo 35
All the variants refer to main transcript and major isoform of NFIX gene) (NM_002501.3) (Q14938). Nomenclature was checked using Mutalyzer website:
https://www.mutalyzer.nl/ND, not determined (due to unavailability of material from both parents).
aMutations previously published with reference to another isoform (NM_001271043.2) that encodes a protein with eight additional amino acids at the N-
terminus.
bCADD (https://cadd.gs.washington.edu/) v1.3 PHRED-like (-10*log10(rank/total)) scaled C-score: ranking a variant relative to all possible substitutions of
the human genome (8.6× 10^9). A scaled C-score≥10: variant is belongs to 10%most deleterious variants; C-score≥20: variant belongs to 1%most delete-
rious variants.
All variants have been submitted to: https://databases.lovd.nl/shared/genes/NFIX.
et al., 2013), is provided in Table 1, and illustrated in Figure 1 and
Supporting Information Figure 7. Detailed individual patient data are
provided in Supporting Materials (Supporting Information Tables 1
and 2). Molecular data are summarized in Figure 2 and Table 2. We
discuss here only those results that are not available in the tables.
3.1 Phenotype
All patients presented with typical facial features of Malan syndrome
(Figure 1; Supporting Information Figure 7). Notably, no patient had
facial features typical for Sotos orWeaver syndromes. The phenotypes
of the four patients (patients 39–42) with variants in the 3′end ofNFIX
were not different from the phenotype of patients with variants in
other NFIX domains. Additional noteworthy data include two patients
(patient 1 and 21) conceived via Artificial Reproduction Technique;
underdeveloped optic nerves in patients 6, 7, 15, 21, 23, 24, 26, 29,
35, 37, 40, 41, and 42; periventricular nodular heterotopias (patients
7 and 23); highly arched palate and dental crowding (patients 5, 29, 33,
37, and 44); sparse hair (patients 24, 25, and 38); loose and soft skin of
their soles (patients 25 and 39); and facial asymmetry (patients 2 and
6). Problems observed in individual patients were an abnormal pelvic
bonemorphology (patient 3); right coxa valga deformity and cox arthri-
tis, cataract, and mitral valve prolapse (patient 5); absent earlobes
(patient 6); mild restriction of elbow and kneemovements (patient 13);
camptodactyly (patient 14); contractures of his hands in early adult-
hood (patient 19); marked brachycephaly (patient 20); periventricu-
lar gliosis (patient 21); plagiocephaly (patient 22); contractures of the
hamstrings, poor peripheral vision, atrial septal defect, and increased
susceptibility for infections (patient 23); large but normally function-
ing kidneys (patient 24); a supraorbital cavernous hemangioma and
choroid fissure cyst (patient 26); curved tibiae (patient 28); central
obstructive apnea, a flaccid larynx, talipes and bilateral hydroceles
(patient 34); three hemangiomas, a small optic chiasm, microcystic
pineal gland, and cortical vision impairment (patient 35); hemiplegic
migraine headaches (patient 37); postural hypotension (patient 38);
grade IV hydronephosis due to bilateral proximal ureteral stenosis, an
inguinal hernia, and brittle toenails (patient 39); gall bladder agenesis,
intestinal malrotation, pulmonary valve stenosis, and severe dilatation
of the pulmonary trunk (patient 42); and a sarcoma of the fifth rib at
age 9 years (patient 43).
3.2 Genotype
Molecular results are listed in Table 2, and their distribution over
the gene is illustrated in Figure 2. We found 18 missense and seven
nonsense variants,14 small deletions and insertions/duplications caus-
ing frameshift and premature termination codons, two in-frame inser-
tions/deletions, and a complex de novo change at the splice acceptor
region of exon 2 consisting of three nucleotide changes (c.28-1G > A,
c.28-12T > A and c.28-13T > A). Parents were negative for all three
variants and paternity was confirmed.
Most variants were in exon 2. Only three variants (mis-
sense variants p.Arg38Cys and p.Arg115Trp; in frame deletion
p.Glu53_Glu59del) had been previously reported (Jazela-Staneck
et al., 2016, Martinez et al., 2015, Priolo et al., 2012). The remaining
variants are novel. We found two missense variants involving residue
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F IGURE 1 AP facial viewof presently reported42 individualswithMalan syndrome.Numbers of individuals in thepanels correspond tonumbers
in the Tables. Ages arementioned below each picture. For detailed descriptions please see Tables and text
Arg116 (p.Arg116Gly; p.Arg116Glu) in three patients (Patients 23,
24, and 25). A different missense change was reported previously
(p.Arg116Pro) (Gurrieri et al., 2015). All observed missense variants
affected amino acids, highly conserved in orthologous and paralogous
NFI proteins except for a change of Thr-260, which is conserved in
the CTF-NFI domain of NFIX only (Supporting Information Figure 2).
All variants were absent from 1000 genomes, ExAC, and gnomAD
databases. In silico analysis ofNFIX variants using CADD v1.3 PHRED-
like C-score suggested that all variants are deleterious (Table 2). Only
seven Malan syndrome-associated variants are in exons 5–8 outside
of the region coding for the N-terminal DNA binding and dimerization
domain. Of these, one is a missense, two are nonsense, and four are
frameshift variants. These patients presented all a typical Malan
phenotype (Supporting Information Table 1; Figure 1 a4, a5, b3, c1, e3,
e6; Klaassens et al., 2015).
All variants for which parents were checked (n = 35) were de novo
except for patient 35, in whom the mother was found to be mosaic for
the NFIX variant in blood using WES (allele count abnormal in six of
the total 44 reads [14%]). She was phenotypically normal, height was
165.1 cm, and had normal intelligence. As a child she had learning dif-
ficulties requiring individualized educational program and as an adult
she had an anxiety disorder.
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F IGURE 2 NFIX cartoon with all reported variants in Malan (underneath the gene) and Marshall-Smith (above the gene) syndrome. The color
legend for missense, nonsense, ins/dels, splicing, and intragenic deletions is shown. Recurring variants are reported with additional circles. Exons
and introns are in scale except introns 1 and 2. Blue: putative DNA binding and dimerization domain of the gene and inside it; green: MH1 (MAD
homology 1) domain and the N-terminal DNA binding (DNAbd) domain; orange: CAAT-box transcription factor–nuclear factor I (CTF-NFI) domain
3.3 RNA analysis
RT-PCR experiments were performed on RNA extracted from fibrob-
lasts of two individuals. In patient 1 harboring the complex de novo
variant c.[28-1G > A;28-12T > A;28-13T > A] at the splice acceptor
of exon 2 the consequence of this changewas investigated by sequenc-
ing of cDNA. Thereby it could be demonstrated that the variant leads
to utilization of an ectopic acceptor splice site, which resulted in an
inclusion of 10 nucleotides of intron 1 into the mRNA that predicted
a frameshift and premature stop codon (p.Asp10Profs*5) (Supporting
Information Figure 3).
In patient 41 carrying c.1116del in exon 8, cDNA sequence analysis
using oligonucleotide primers specific for different protein-coding iso-
forms showed that the mutant allele was almost absent in the mRNA,
thereby indicating degradation by NMD (Supporting Information
Figure 4).
4 DISCUSSION
We report here on a series of 45 individuals with molecularly con-
firmed Malan syndrome, and compare the findings to those of 35 pre-
viously reported individuals (Supporting Information Tables 1–3). This
has allowed us to refine themajor characteristics ofMalan syndrome.
Malan syndrome is known as an overgrowth syndrome. However,
the combined data from previously published and presently reported
cases reveals that birth weight is above the 2 SDS in only a minority
of patients, but birth weight is above the mean in ∼90% of patients.
Head circumference is > 2 SDS in 37% of newborns. Postnatal height
and head size are typically > 2 SDS but height may decrease with age
as of 13 adults only six still have a height> 2 SDS. Head circumference
remained > 2SD in 10/13 adults. Bone age is advanced 1 year or more
in 80% of patients in whom this was evaluated but data are available
from only 50 out of 79 patients, with likely ascertainment bias as this
is more frequently determined in those who show overgrowth. The
growth pattern in Malan syndrome resembles the growth pattern in
Sotos syndrome in which initial overgrowth is very common but adult
height is above 2 SDS in only one-third of individuals (Tatton-Brown
et al., 2013).
Intellectual disability is invariably present, but detailed studies
are lacking. Preliminary results of ongoing studies in the presently
reported group of individuals indicate that severity is varying from
moderate to severe, and exceptionally mild intellectual disability is
present. Independently, several referring physicians have indicated
that their patients demonstrate anxieties and are extremely sensitive
to noise, which seems to worsen their anxious behavior. In our series,
anxieties were mentioned spontaneously by referring clinicians in the
item “Behavioral characteristics” in 52% of individuals. The behavior
may culminate in crises during which patients may become aggressive
to themselves and to others. More detailed cognitive and behavioral
studies are in progress to substantiate the behavior using dedicated
psychological instruments.
Neuro-imaging yieldednormal results inmost patients. If abnormal-
ities were present, then these were usually nonspecific findings such
as enlarged ventricles and a small callosal body. However, cortical dys-
plasias and periventricular nodular heterotopias do occur occasion-
ally as well, as has been previously reported (Klaassens et al., 2015).
Seizures and/or EEG abnormalities occurred in 18% of the presently
reported patients and 27% of all known patients.
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The most characteristic facial findings include a long or triangu-
lar face, prominent forehead, depressed nasal bridge, deeply set eyes,
down-slanting palpebral fissures, short nosewith antevertednares and
upturned tip, long philtrum, small mouth that is often held open, with a
thin upper vermillion in a cupid bow shape, an everted lower lip, and
a prominent chin (Figure 1). With age the face seems to become more
elongated, the chin becomes more prominent, skin folds deeper, and
the mouth tends to become more open (Supporting Information Fig-
ure 7c). Visual problems are common (76%) but often limited to non-
specific abnormalities such as strabismus, myopia, and hypermetropia,
and nystagmus is uncommon. Thirteen of the presently reported indi-
viduals had variable degrees of underdeveloped optic nerves, which
has also been reported in three earlier reported patients (Dolan et al.,
2010; Priolo et al., 2012). These individuals hadboth point variants and
deletions ofNFIX. Underdevelopedoptic nerves have alsobeennoticed
in Marshall-Smith syndrome (Shaw et al., 2010). Skeletal anomalies
are frequent, especially a slender habitus (59%) together with long
hands (60%) (Supporting Information Figure 7b), sometimes described
as resembling Marfan syndrome. Other signs such as scoliosis, pectus
carinatum, or excavatum occur at varying frequencies (Table 1).
When comparing characteristics of the 56 individuals with Malan
syndrome caused by NFIX point mutations to the 24 individuals with
deletions ofNFIX and a variable number of other genes, there were no
significant differences in growth pattern, cognitive impairment, facial
characteristics, or skeletal manifestations. Individuals with an NFIX
containing microdeletion demonstrated seizures and EEG abnormali-
ties more frequently (11/24 in deleted patients vs. 10/56 in patients
with point variants). The increased prevalence of seizures/epilepsy
may be explained by the presence of a contiguous gene disorder.
Deletions involving CACNA1A that is located 109 kb from NFIX seem
to play a particular role. Of the 14 individuals in whom the deleted
region includedCACNA1A,10developed seizures. In contrast, only one
patient has been reported with seizures in whom the deletion did not
include CACNA1A (Jezela-Stanek et al., 2016). Klaassens and cowork-
ers (2015) reported a single patient with cyclical vomiting responsive
to pizotifen and a literature patientwho had episodic ataxia at age nine
years. None of the present patients with NFIX deletions showed these
symptoms.
We compared the findings in Malan syndrome to those reported in
Marshall-Smith syndrome (Shaw et al., 2010; Van Balkom et al., 2011),
an allelic disorder causedbyvariants inNFIX that is postulated to result
from a dominant-negative action (Table 1; Figure 2). Individuals with
Marshall-Smith syndrome differmarkedly in growth pattern, both pre-
natally and postnatally. Although the entity is often categorized among
the overgrowth syndromes, 20% of newborns with Marshall-Smith
syndrome have in fact a birth weight below the 3rd centile, none have
macrocephaly, and almost all have growth parameters below the 3rd
centile postnatally. The wrongful assignment of Marshall-Smith syn-
drome as an overgrowth disorder is caused by the seemingly advanced
bone age of the distal extremities, which is a manifestation of the
dysostosis in this disorder (Shaw et al., 2010). Cognitive impairment
has been present in all known individuals with Marshall-Smith syn-
drome (VanBalkomet al., 2011).Neuro-imagingyields similar results in
both entities. There are major differences in facial morphology due to
the absence of macrocephaly and presence of proptosis, underdevel-
oped midface and small chin in Marshall-Smith syndrome. Some facial
findings such as a prominent forehead, short nose with anteverted
nares, and everted lower lip are present in both entities, but gener-
ally the facial abnormalities in Marshall-Smith syndrome are more
pronounced. A slender habitus is uncommon in Marshall-Smith and
sternum abnormalities have been recorded only occasionally. Scoliosis
is common in both entities, but only in individuals withMarshall-Smith
syndrome the scoliosis remains progressive also into adulthood, likely
due to the marked osteopenia (RCH, personal observation). Hypertri-
chosis occurs only in Marshall-Smith syndrome, and gingiva hypertro-
phy is almost completely limited to individuals with this entity. In only
very few individuals with either entity one has considered the other
diagnosis. In the present series, this occurred in patient 43.Malan syn-
dromeandMarshall-Smith syndrome seem tobe two separate entities.
However, the number of reported individuals remains small and with
additional reports clues for a continuous spectrummay still be found.
Malan syndrome has been suggested to resemble Weaver
syndrome and Sotos syndrome. We compared the three entities
(Table I) and found some resemblances but also many differences.
The growth pattern in these entities is similar: individuals with Sotos
and Weaver syndrome are also frequently large for gestational age at
birth, grow > 2 SDS in the first few years of life, but adult height falls
typically within two SDS of themean. Developmental delay is common
in all three entities but in Malan syndrome there is typically moderate
to severe intellectual disability, while Sotos andWeaver patients have
typically mild to moderate disability, although there is a wide distribu-
tion of cognitive and functional abilities (Lane, Milne, & Freeth, 2016).
Facially, individuals with Malan, Sotos, and Weaver syndrome share
macrocephaly and a prominent forehead, and, in Sotos and Malan
syndrome, a long face. The other facial signs differ between the three
entities. We conclude that usually differentiating the three entities
is possible by clinical evaluation alone, and that this differentiation
is of major importance for adequate care and counseling of patients
and their families. We propose that Malan syndrome should not be
indicated as “Sotos syndrome type 2″ because of the clear differences
between the two entities.
Together with the patient cohort presented here, a total of 51
different intragenic NFIX variants have been reported in 56 unrelated
patients with Malan syndrome (Table 2). Twenty-seven of the variants
observed in Malan syndrome were nonsense, frameshift and splice
site variants predicting premature stop codons mostly in the 5′ part
of the mRNA. It is likely that these mutated mRNAs are cleared by
nonsense-mediated decay (NMD), thereby leading to haploinsuffi-
ciency (Lykke-Andersen & Jensen 2015). Experimental evidence for
this mechanism has previously been provided for a small number of
variants causing Malan syndrome (Malan et al., 2010). Twenty-three
different missense variants have been identified, most of these (22
out of 23) are located in the DNA binding and dimerization domain.
There is a predominant involvement of basic residues (in 12 of the
23 missense variants), and some have been altered more than once
(at positions Arg38; Arg115; Arg116; Lys125) (Gurrieri et al., 2015;
Jezela-Stanek et al., 2016; Lu et al., 2017; Martinez et al., 2015;
Priolo et al., 2012). We found a clustering of NFIX missense variants
10 PRIOLO ET AL.
involving positively charged amino acids (at positions Lys 113, Arg115,
Arg116, Arg121, Lys125, and Arg128) in a small region of 15 residues.
Both arginine and lysine are frequently located in protein-activating
or binding sites, and their charge distribution is ideal for binding
negatively charged groups (LaCasse et al., 1995; Yao et al., 2016). A
putative nuclear localization (NLS) domain encompassing amino acids
36–50 of NFIX (RKRKYFKKHEKRMSK) is predicted by cNLS mapper
(url: nls-mapper.iab.keio.ac.jp/). This domain is completely overlapping
with NLS1 in the paralogous NFIA protein. Previous studies on NFIA
demonstrated that both NLS1 and NLS2 are required for the full
translocation of the protein to the nucleus (Imagawa, Sakaue, Tanabe,
Osada, & Nishihara, 2000). The domains are highly conserved in all
NFI proteins and are located near the DNA binding domain (Imagawa
et al., 2000). Three Malan syndrome-associated missense variants
are localized at or immediately adjacent tothe putative NLS. The NLS
regions are usually located near DNA-binding domains (LaCasse et al.,
1995). Based on these suggestions it is plausible that the mutated
proteins harboringmissense variantsmay either fail to shuttle into the
nucleus or bind DNA, thus explaining haploinsufficiency.
There are striking genotype-phenotype correlations between
Malan syndrome and Marshall-Smith syndrome. Variants associated
with Marshall-Smith syndrome have exclusively been found in regions
outside of those coding for the DNA binding and dimerization domain,
especially in exons 6–8 and sometimes in exons 9 and 10 (Figure 2).
For several Marshall-Smith-associated variants it has been demon-
strated thatmutantmRNAdoes not undergoNMD (Malan et al., 2010;
Schanze et al., 2014). Previous evidence suggested that variants asso-
ciated with Malan syndrome are instead restricted to the 5′ part of
the gene encoding for the DNA binding and dimerization domain. This
was indeed true for most of the novel variants reported in our study
(Figure 2). In contrast, however, we identified four variants (in five indi-
viduals affected by Malan syndrome) that were located within the 3′
part of the gene (in exons 6, 7, and 8). Another variant in this part of
the gene, p.Gln338*, has been reported previously in an individual with
Malan syndrome (Klaassens et al., 2015). Their phenotypes (P39, P40,
P41, P42 and Klaassens patient) do not differ in any way from those of
other individuals with Malan syndrome. Alignment of the correspond-
ing mutated NFIX proteins in Malan syndrome and Marshall-Smith
syndrome predicts that despite the overlap in the genomic positions of
variants, the position of the translational stop codon strictly separates
Marshall-Smith syndrome—fromMalan syndrome-associated variants
(Supporting Information Figures 5–6). We have also shown here for a
Malan syndrome-associated frameshift variant with the most 3′ posi-
tion (c.1116del) that the mutant mRNA is almost absent, thus con-
firming the rule that haploinsufficiency is the mechanism underlying
Malan syndrome. It cannot be excluded for Marshall-Smith syndrome-
associated variants that aside from their ability to generate expressed
mutant proteins with conserved DNA-binding capacities, these pro-
teins might also have specific functions mediated by their altered C-
terminus. However, the present analysis suggests that there is nomotif
shared by all Marshall-Smith syndrome-associated mutant NFIX pro-
teins (Supporting Information Figures 5 and 6).
Malan syndrome is typically caused by a de novo mutational event
(Table 2). However, one of the individuals presented here had a variant
inherited from a mosaic mother who was phenotypically normal but
who had some learning and behavioral issues that may point to a very
mild presentation. There are two other reports of variants that have
been inherited. Inone, thep.Arg121Promissensevariantwas inherited
from a mother who presented with tall stature (no other clinical data
provided) (Yoneda et al., 2012) andNimmakayalu et al. (2013) reported
two sisters with Malan syndrome and a partial NFIX deletion, suggest-
ing germline mosaicism in one of the parents. Both parents were phe-
notypically normal and the deletion was not detected in their lympho-
cytes. These observations stress the importance of careful evaluation
of parents and proper counseling about recurrence risks in families
withMalan syndrome.
Individuals with Malan syndrome exhibit some symptoms reminis-
cent of Marfan or Marfan-like syndromes caused by dysregulation of
the TGF-𝛽 pathway (slender body build, long fingers, scoliosis, and pec-
tus formation). A possible pathophysiological link could be the interac-
tionofNFI proteinswith Sloan-KetteringoncogeneSKI (Taraporeet al.,
1997), the protein mutated in Shprintzen-Goldberg syndrome (Doyle
et al., 2012). The SKI protein in turn regulates SMAD-dependent TGF-
𝛽 signaling (Luo et al., 2004). Consistent with a possible relationship
of Malan syndrome with Marfan-like connective tissue disorders, one
individual in the present series had a marked pulmonary artery dilata-
tion, and two of the 15 individuals from the present series who under-
went aortic evaluation, had an enlarged aorta (one at age 3 years). In
the literature, two other individuals with Malan syndrome (one with
a frameshift variant and one with a whole gene deletion) have been
reported with aortic dilatation (Nimmakayalu et al., 2013; Oshima
et al., 2017), and one individual with Marshall-Smith syndrome has
been reported with aortic root dilatation (Aggarwal, Nguyen, Rivera-
Davila, & Rodriguez-Buritica, 2017). The true frequency, spontaneous
course and clinical significance of aortic dilatations in Malan syn-
drome andMarshall-Smith syndrome currently remains uncertain, but
it seems prudent to evaluate all individuals with either syndromes for
enlargement of the large vessels, until reliable data provewhether this
is truly indicated or not.
We conclude that Malan syndrome is an overgrowth syndrome
that presents in infancy and childhood, but overgrowth is less marked
in adulthood as adult height is > 2 SDS in half of them. Macro-
cephaly remains present in 75%. There are significant and recog-
nizable differences between Malan syndrome and other overgrowth
syndromes, including Sotos and Weaver syndrome, and we there-
fore challenge the designation of “Sotos syndrome type 2″ for Malan
syndrome. There may be an increased risk to develop aortic dilata-
tion in Malan syndrome, but more data are needed to determine
whether long-term surveillance is indicated. There may be a spe-
cific behavioral phenotype, characterized especially by anxieties, but
this requires further detailed studies that are presently in progress.
Except for the occurrence of epilepsy, likely due to deletion of
CACNA1A, there is no difference in phenotype between individuals
with 19p13.2microdeletions encompassingNFIX and those with intra-
genic mutations. NFIX variants that cause Malan syndrome are typ-
ically located in exons coding for the DNA binding and dimerization
domain, with few exceptions. As for truncating variants elsewhere
in NFIX, the mechanisms leading to haploinsufficiency rather than
PRIOLO ET AL. 11
dominant-negative effects for Malan syndrome-associated frameshift
variants in the 3′ exons of the gene are likely related to the position
of the translational stop codon and clearance of the mutant mRNA by
NMD.
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